ES2202560T3 - Triciclicos sustituidos. - Google Patents

Triciclicos sustituidos.

Info

Publication number
ES2202560T3
ES2202560T3 ES97308645T ES97308645T ES2202560T3 ES 2202560 T3 ES2202560 T3 ES 2202560T3 ES 97308645 T ES97308645 T ES 97308645T ES 97308645 T ES97308645 T ES 97308645T ES 2202560 T3 ES2202560 T3 ES 2202560T3
Authority
ES
Spain
Prior art keywords
alkyl
arthritis
phenyl
acid
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97308645T
Other languages
English (en)
Spanish (es)
Inventor
Nicholas James Bach
Robert Delane Dillard
Susan Elizabeth Draheim
John Michael Morin, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2202560T3 publication Critical patent/ES2202560T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles
    • C07D209/88Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572Five-membered rings
    • C07F9/5728Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Fats And Perfumes (AREA)
ES97308645T 1996-10-30 1997-10-29 Triciclicos sustituidos. Expired - Lifetime ES2202560T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2984996P 1996-10-30 1996-10-30
US29849P 1996-10-30

Publications (1)

Publication Number Publication Date
ES2202560T3 true ES2202560T3 (es) 2004-04-01

Family

ID=21851210

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97308645T Expired - Lifetime ES2202560T3 (es) 1996-10-30 1997-10-29 Triciclicos sustituidos.

Country Status (26)

Country Link
EP (1) EP0839806B1 (enExample)
JP (1) JP2001503055A (enExample)
KR (1) KR20000049210A (enExample)
CN (1) CN1233176A (enExample)
AR (1) AR010050A1 (enExample)
AT (1) ATE244703T1 (enExample)
AU (1) AU734096B2 (enExample)
BR (1) BR9713261A (enExample)
CA (1) CA2269203A1 (enExample)
CO (1) CO4920250A1 (enExample)
CZ (1) CZ136899A3 (enExample)
DE (1) DE69723393T2 (enExample)
DK (1) DK0839806T3 (enExample)
EA (1) EA003992B1 (enExample)
ES (1) ES2202560T3 (enExample)
ID (1) ID18685A (enExample)
IL (1) IL129481A0 (enExample)
NO (1) NO314899B1 (enExample)
NZ (1) NZ335246A (enExample)
PE (1) PE10999A1 (enExample)
PL (1) PL332896A1 (enExample)
PT (1) PT839806E (enExample)
TR (1) TR199900956T2 (enExample)
TW (1) TW513428B (enExample)
WO (1) WO1998018464A1 (enExample)
YU (1) YU19299A (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2301586A1 (en) * 1997-08-28 1999-03-04 William Louis Macias Method for treatment of non-rheumatoid arthritis
HUP0102981A3 (en) 1998-03-31 2002-10-28 Shionogi & Co Pyrrolo[1,2-a]pyrazine derivatives and pharmaceutical compositions thereof
IL129484A0 (en) * 1998-04-17 2000-02-29 Lilly Co Eli Substituted tricyclics
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
TR200003194T2 (tr) 1998-05-01 2001-03-21 Eli Lilly And Company Hastalık tedavisine mahsus sPLA2 önleyici bileşikler
KR20010034881A (ko) 1998-05-21 2001-04-25 시오노 요시히코 sPLA2 억제 효과를 갖는 피롤로[1,2-b]피리다진 유도체
ATE329619T1 (de) 1998-10-14 2006-07-15 Shionogi & Co Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschäden
US6448284B1 (en) * 1998-12-22 2002-09-10 Eli Lilly And Company Substituted tricyclics
AU6015600A (en) 1999-07-19 2001-02-05 Shionogi & Co., Ltd. Tricyclic compounds having spla2-inhibitory activities
US6673781B1 (en) 1999-08-02 2004-01-06 Shionogi & Co., Ltd. Tricyclic compounds having sPLA2-inhibitory activities
US6787545B1 (en) 1999-08-23 2004-09-07 Shiongi & Co., Ltd. Pyrrolotriazine derivatives having spla2-inhibitory activities
MY125942A (en) 1999-09-07 2006-09-29 Upjohn Co Aminoalkoxy carbazoles for the treatment of cns diseases
US6756376B1 (en) 1999-11-15 2004-06-29 Shionogi & Co., Ltd. Tricyclic azaindolizine derivatives having an sPLA2-inhibitory activities
WO2001049323A1 (en) * 2000-01-06 2001-07-12 Eli Lilly And Company Combination therapy for the treatment of inflammatory and respiratory diseases
JPWO2002000621A1 (ja) 2000-06-29 2004-04-22 塩野義製薬株式会社 X型sPLA2阻害作用を有する化合物
WO2002000256A1 (fr) 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedes contre la cirrhose
US6872743B2 (en) 2000-12-18 2005-03-29 Eli Lilly And Company sPLA2 inhibitors
TWI314457B (enExample) 2001-03-19 2009-09-11 Shionogi & Co
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
US8329913B2 (en) 2004-10-29 2012-12-11 Zeria Pharmaceutical Co., Ltd. Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof
ES2924728T3 (es) 2015-06-15 2022-10-10 Raziel Therapeutics Ltd Derivados de carbazol para el tratamiento de enfermedades fibróticas, así como de síntomas y afecciones relacionados con las mismas
CN112409493B (zh) * 2020-08-12 2022-09-30 浙江工业大学 一种重组融合酶及其在乙醛酸甲酯合成中的应用
US12440370B2 (en) 2020-10-21 2025-10-14 Purewick Corporation Apparatus with compressible casing for receiving discharged urine
US12208031B2 (en) 2020-10-21 2025-01-28 Purewick Corporation Adapters for fluid collection devices
US12257174B2 (en) 2020-10-21 2025-03-25 Purewick Corporation Fluid collection assemblies including at least one of a protrusion or at least one expandable material

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3479391A (en) * 1966-10-03 1969-11-18 Squibb & Sons Inc Delta**3,14-17alpha-hydroxy-norprogesterone and esters
US3939177A (en) * 1972-11-22 1976-02-17 Sterling Drug Inc. 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors

Also Published As

Publication number Publication date
PT839806E (pt) 2003-11-28
NO991831L (no) 1999-06-21
PE10999A1 (es) 1999-02-10
DE69723393T2 (de) 2004-06-09
EP0839806B1 (en) 2003-07-09
KR20000049210A (ko) 2000-07-25
EA199900305A1 (ru) 1999-12-29
NO991831D0 (no) 1999-04-16
NZ335246A (en) 2001-09-28
ATE244703T1 (de) 2003-07-15
CO4920250A1 (es) 2000-05-29
AR010050A1 (es) 2000-05-17
NO314899B1 (no) 2003-06-10
TR199900956T2 (xx) 1999-07-21
DK0839806T3 (da) 2003-10-27
CA2269203A1 (en) 1998-05-07
AU5149498A (en) 1998-05-22
EP0839806A1 (en) 1998-05-06
EA003992B1 (ru) 2003-12-25
BR9713261A (pt) 2000-03-28
YU19299A (sh) 2000-03-21
WO1998018464A1 (en) 1998-05-07
TW513428B (en) 2002-12-11
IL129481A0 (en) 2000-02-29
CN1233176A (zh) 1999-10-27
ID18685A (id) 1998-04-30
JP2001503055A (ja) 2001-03-06
PL332896A1 (en) 1999-10-25
AU734096B2 (en) 2001-06-07
CZ136899A3 (cs) 1999-09-15
DE69723393D1 (de) 2003-08-14

Similar Documents

Publication Publication Date Title
AU734096B2 (en) Substituted tricyclics
AU753436B2 (en) Substituted tricyclics
EP0772592B1 (en) 1H-INDOLE-1-FUNCTIONAL sPLA 2 INHIBITORS
US6177440B1 (en) Substituted tricyclics
JP2001503055A5 (enExample)
ES2213668T3 (es) Compuestos triciclicos sustituidos utiles en enfermedades inducidas por spla2.
US6713645B1 (en) Substituted tricyclics
US6448284B1 (en) Substituted tricyclics
US20040087796A1 (en) Substituted carbazoles as inhibitors of spla2
HK1010546A (en) Substituted tricyclics
HUP9903545A2 (hu) Helyettesített triciklusos vegyületek, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
HK1024912A (en) Substituted carbazoles, process for their preparation and their use as spla2 inhibitors
HK1024911A (en) Substituted carbazoles, process for their preparation and their use as spla2 inhibitors
HK1025091A (en) Substituted tricyclics useful in spla2 induced diseases
MXPA99003588A (en) Triciclic composites substitui